Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, announced the publication of Phase 1a clinical data for LP-184 (zirdafulven), also being developed as STAR-001, in patients with recurrent glioblastoma (“GBM”). Published in…
Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced the closing of its previously announced registered direct offering of 3,669,725 shares of common…
Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share in a registered direct offering expected…
Lantern Pharma (NASDAQ: LTRN) will present the growth plan for Open-Medicine AI (“OMAI”), its wholly owned subsidiary developing a multi-agentic AI platform for drug development, during a live webinar today at 12:30 p.m. Eastern. CEO…
Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, covering methods of using LP-284…
Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced it will host a live webinar Sept. 23 at 12:30 p.m. Eastern to present the…
Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB(TM) platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules…
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with…
Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, which showed a 48%…
• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications • CEO Panna Sharma says AI is compressing development timelines and cost structures across oncology Lantern Pharma (NASDAQ: LTRN), an AI-driven…
Lantern Pharma (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR(R) platform, will host a webcast at 9 a.m. ET (6 a.m. PT) on Thursday, Nov. 13, 2025, to review third-quarter…
Lantern Pharma (NASDAQ: LTRN) will present its commercially deployed AI research platforms, predictBBB.ai and LBx-AI, at the inaugural AI for Biology and Medicine symposium hosted by the University of North Texas. The company will showcase…
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its RADR(R) AI platform to transform oncology drug discovery and development, presented clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual…
Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery, announced that its management team will present at the ThinkEquity…
Lantern Pharma (NASDAQ: LTRN) is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs. The company was featured in a…
In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of dollars. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and…
Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug…
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. The company recently “completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM)…
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, announced the successful completion of its Phase 1a clinical trial for LP-184 (NCT05933265), which met all primary endpoints, showing a favorable safety and pharmacokinetic profile with early…
Lantern Pharma (NASDAQ: LTRN) recently unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). “The technology is integrated into…